Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Other Non-Current Assets (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Other Non-Current Assets for 14 consecutive years, with $942000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets changed N/A year-over-year to $942000.0, compared with a TTM value of $942000.0 through Sep 2025, changed N/A, and an annual FY2022 reading of $42000.0, changed 0.0% over the prior year.
  • Other Non-Current Assets was $942000.0 for Q3 2025 at Alaunos Therapeutics, down from $997000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $13.9 million in Q1 2023 and bottomed at $1000.0 in Q2 2023.
  • Average Other Non-Current Assets over 4 years is $1.4 million, with a median of $185000.0 recorded in 2021.
  • Peak annual rise in Other Non-Current Assets hit 32995.24% in 2023, while the deepest fall reached 99.8% in 2023.
  • Year by year, Other Non-Current Assets stood at $42000.0 in 2021, then changed by 0.0% to $42000.0 in 2022, then plummeted by 97.62% to $1000.0 in 2023, then skyrocketed by 94100.0% to $942000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for TCRT at $942000.0 in Q3 2025, $997000.0 in Q2 2025, and $1.1 million in Q1 2025.